1. Home
  2. MPV vs IMUX Comparison

MPV vs IMUX Comparison

Compare MPV & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Barings Participation Investors

MPV

Barings Participation Investors

HOLD

Current Price

$16.32

Market Cap

182.5M

Sector

Finance

ML Signal

HOLD

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$16.27

Market Cap

209.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MPV
IMUX
Founded
1988
2016
Country
United States
United States
Employees
N/A
66
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
182.5M
209.2M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
MPV
IMUX
Price
$16.32
$16.27
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$36.00
AVG Volume (30 Days)
24.3K
140.8K
Earning Date
01-01-0001
05-14-2026
Dividend Yield
8.71%
N/A
EPS Growth
N/A
38.00
EPS
1.71
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$9.45
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.05
$0.51
52 Week High
$21.00
$16.86

Technical Indicators

Market Signals
Indicator
MPV
IMUX
Relative Strength Index (RSI) 51.33 66.47
Support Level $16.04 $0.74
Resistance Level $17.57 N/A
Average True Range (ATR) 0.26 1.04
MACD 0.04 0.28
Stochastic Oscillator 69.33 90.27

Price Performance

Historical Comparison
MPV
IMUX

About MPV Barings Participation Investors

Barings Participation Investors is a diversified closed-ended management investment company. The Trust's investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. Its principal investments are privately placed, below-investment grade, long-term debt obligations including bank loans and mezzanine debt instruments. The company invests in various sectors such as aerospace and defense; automotive; building materials; consumer products and others.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Share on Social Networks: